Pharma Giant Expands with Strategic Acquisition in Singapore
The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations.
Strides Pharma Science Limited has successfully completed the acquisition of Amexel Pte. Ltd., Singapore, through its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited. This strategic acquisition, finalized on March 19, 2025, marks a significant expansion in Strides' global footprint, particularly enhancing its capabilities in the pharmaceutical sector. Strides Pharma Science Ltd is known for its diverse business segments, including Pharma Generics, Branded Generics, and Institutional Business, which cater to a wide range of markets and therapeutic areas.
The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations. With a robust pipeline of approved products and a strategic focus on growth, Strides aims for a 12-15 per cent revenue increase in FY25, with significant contributions expected from the US market. This acquisition aligns with Strides' inorganic growth strategy, reinforcing its market position and offering new opportunities for expansion.
Strides Pharma Science Ltd is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of pharmaceutical products sold across more than 100 countries. The company has a diverse portfolio, including Pharma Generics, Branded Generics, and Institutional Business, with a strong presence in regulated markets such as the US, Europe, and Australia. Strides is recognized as a leading producer of soft gelatine capsules and has a strategic focus on IP-based product licensing and global marketing partnerships.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products. Strides operates seven manufacturing facilities, four of which are USFDA-approved, ensuring high-quality production standards. The company's recent restructuring efforts and strategic acquisitions are aimed at reducing debt and enhancing operational efficiency, positioning it for sustained growth in the coming years.
Today, the stock of Strides Pharma Science Limited is trading at Rs 654. The stock has a 52-week high of Rs 804.40 and a 52-week low of Rs 329.76 per share. Strides Pharma Science Limited has a market capitalization of over Rs 6,000 crore. Over the past year, the stock is up by 80 per cent and gave multibagger returns of over 300 per cent in 3 years with a price-earnings (PE) ratio of 20
Disclaimer: The article is for informational purposes only and not investment advice.